Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...
Cambium Oncology is pleased to share that their lead drug candidate, ANT308, recently demonstrated outstanding single-agent efficacy and safety in preclinical studies. The drug is mutation-agnostic, ...
It is also under development for paraganglioma and pheochromocytoma as second line therapy It was also under development for the treatment of primary mediastinal large B cell lymphoma, metastatic ...
It is also under development for paraganglioma and pheochromocytoma as second line therapy It was also under development for the treatment of primary mediastinal large B cell lymphoma, metastatic ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback